Patents by Inventor Mark Andrew Kroenke

Mark Andrew Kroenke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of celiac disease with IgA
    Patent number: 8313730
    Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: November 20, 2012
    Inventors: Michael R. Simon, Mark Andrew Kroenke
  • TREATMENT OF CELIAC DISEASE WITH IgA
    Publication number: 20120045517
    Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
    Type: Application
    Filed: October 31, 2011
    Publication date: February 23, 2012
    Inventors: Michael Richard Simon, Mark Andrew Kroenke
  • Treatment of celiac disease with IgA
    Patent number: 8119104
    Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: February 21, 2012
    Inventors: Michael Richard Simon, Mark Andrew Kroenke
  • TREATMENT OF CELIAC DISEASE WITH IgA
    Publication number: 20110117143
    Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.
    Type: Application
    Filed: January 25, 2011
    Publication date: May 19, 2011
    Inventors: Michael Simon, Mark Andrew Kroenke